Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Tom H. Johnston And NotOntario

List of bibliographic references

Number of relevant bibliographic references: 10.
Ident.Authors (with country if any)Title
000077 Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada]Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
000787 Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert ; Tacey X. Viegas ; Michael D. Bentley ; Zhihao Fang ; Bekir Dizman ; Kunsang Yoon ; Rebecca Weimer ; Paula Ravenscroft ; Tom H. Johnston ; Michael P. Hill ; Jonathan M. Brotchie ; Randall W. MoreadithRotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
000D50 Philippe Huot [Canada] ; Tom H. Johnston ; Naomi P. Visanji ; Tayyeba Darr ; Donna Pires ; Lili-Naz Hazrati ; Jonathan M. Brotchie ; Susan H. FoxIncreased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.
000F18 Susan H. Fox [Canada] ; Tom H. Johnston ; Qin Li ; Jonathan Brotchie ; Erwan BezardA critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.
001309 James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada]The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
001944 Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
001D22 Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease
001F06 Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates
003402 Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
003652 Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024